SWS IPO and Listing on the SSE STAR Market
SWS is listed on the SSE Science and Technology Innovation Board, the first in the blood purification industry.
SWS Bell Ringing Ceremony of Public Listing
[Chongqing, China, December 26, 2022] SWS Hemodialysis Care Co., Ltd. (SSE: 688410) was listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE)，the first company based in Chongqing and the first in the blood purification industry, starting off a new chapter in the capital market.
Mr. GAO Guangyong, Chairman of the Board of Directors of SWS, delivered a speech at the bell ringing ceremony, saying: "The listing is a milestone in the history of SWS. The company will continue to abide by laws and regulations, respect the supervision of regulators, fulfill its social responsibilities while creating long-term value for our shareholders. We’ll work to build a virtuous cycle of products and capital, give back to our employees, shareholders and the society with excellent business performance."
Mr. Gao added that SWS will continue to focus on the development of the blood purification industry. Driven by national policies and market demand, SWS aims to build a world leading brand committed to the research and industrial application of blood purification equipment, disposables, chain dialysis centers and information management system through independent innovation and incorporating advanced technologies and smart manufacturing.
SWS issued 36.19 million new shares at a price of CNY32.30 per share. SWS reported a total of 144.73 million shares after the offering.
It is reported that SWS raised CNY1.169 billion in the listing, which will be invested in projects of blood purification equipment, high-value disposables, R&D center construction, marketing network upgrade, remote operation and maintenance service platform, and also to supplement working capital.
Industry insiders pointed out that SWS raised CNY1.169 billion, the best player among new listings in Chongqing this year.
According to the SWS preliminary earnings estimate of 2022, during the reporting period, the company registered an operating income of CNY382 million, a year-on-year increase of 34.85%. The net profit attributable to the owners of the parent company was CNY58.4757 million, jumping 200.29% from the previous year. The company has a market cap of over CNY5 billion as of press time.
SWS is a national high-tech enterprise specializing in the research and development, production and sales of blood purification equipment and disposables, and in providing chain hemodialysis medical services. The company has developed hemoperfusion machines, hemodialysis machines and continuous renal replacement treatment (CRRT) equipment based on original, innovative core technologies. SWS has independently developed hemodialyzer, dialysis tubing, hemoperfusion cartridge, hemodialysis concentrate fluid/powder and other disposables. SWS products are widely used in the treatment of various diseases such as acute and chronic renal failure, uremia, multiple system failure and poisoning. So far, tens of thousands of SWS machines have been installed in over a thousand hospitals across China and exported to more than 60 countries and regions around the world.